TEST BANK FOR CLAYTON’S BASIC PHARMACOLOGY FOR
NURSES 19TH EDITIONBY MICHELLE J. WILLIHNGANZ,
SAMUEL L. GUREVITZ, BRUCE CLAYTON COMPLETE
,Chapter 01: Drug Definitions, Standards, and Information Sources Willihn
ganz: Clayton’s Basic Pharmacology for Nurses, 19th Edition
MULTIPLE CHOIC
E
1. Which name identifies a drug listed by the US Foo
d andDrug Administration (FDA)?
a. Brand
b. Nonproprietary
c. Official
d. Trademark
ANS: C
The official name is the name under which a drug is
listed by the FDA. The brand name, or trademark, is t
he name given to a drug by its manufacturer. The non
DIF: Cognitive
proprietary, 6 g Level: 6 g Knowledge
or generic, name is providedREF: 6 g p. 6 g 9
by6 gthe United
OBJ: 6 g 1NAT: 6 g NCLEX 6 g Client 6 g Needs 6 g Category:
States Adopted Names Council.
6g Safe, 6 g Effective 6gCareEnvironment 6g TOP: Nursing
6g Process 6 g Step: 6 g Assessment
CON:
Patient 6 g Education
2. Which 6 g source 6 g contains 6 g information 6 g specific 6 g to 6 g nutritional 6 g supplements?
a. USP 6 g Dictionary 6 g of 6 g USAN 6 g & 6gInternational 6 g Drug 6 g Names
b. Natural 6 g Medicines 6 g Comprehensive 6 g Database
c. United 6 g States 6 g Pharmacopoeia/National 6 g Formulary 6 g (USP 6 g NF)
d. Drug 6 g Interaction 6 g Facts
ANS: 6 g C
United 6gStates 6gPharmacopoeia/National 6gFormulary 6gcontains 6ginformation 6gspecific 6gto
6gnutriti 6gonalsupplements. 6 g USP 6 g Dictionary 6 g of 6 g USAN 6 g & 6 g International 6 g Drug
6 g Names 6 g is 6 g a 6 g compilat 6gion 6 g of 6 g drug8hnames, 6 g pronunciation 6 g guide, 6 g and
6 g possible 6 g future 6 g FDA 6 g approved 6 g drugs; 6 g it 6 g d 6goes 6gnot 6ginclude 6gnutritional
6gsupplements. 6gNatural 6gMedicines 6gComprehensive 6gDatabase 6gc 6gontains
evidence-
based 6 g information 6 g on 6 g herbal 6 g medicines 6 g and 6 g herbal 6 g combination 6 g products;
6 g it 6 g does 6 g notincl 6gude 6 g information 6 g specific 6 g to 6 g nutritional 6 g supplements. 6 g Drug
6 g Interaction 6 g Facts 6 g contains 6 g co 6gmprehensive 6 g information 6 g on 6 g drug
6 g interaction 6 g facts; 6 g it 6 g does 6 g not 6 g include 6 g nutritional 6 g supp 6 g lements.
DIF: Cognitive 6 g Level: 6 g Knowledge REF: p. 6 g 4
OBJ: 6 g 3NAT: 6 g NCLEX 6 g Client 6 g Needs 6 g Category:
6 g Physiological 6gIntegrity
TOP: Nursing 6 g Process 6 g Step: 6 g Assessment 6 g CON: Nutrition 6g | 6 g Patient 6 g Education
3. Which 6 g drug reference 6 g contains 6 g drug 6 g monographs
6g 6 g that 6 g describe 6 g all 6g drugs 6 g in 6 g a
6 g therapeutic 6 g class?
a. Drug 6 g Facts 6 g and 6 g Comparisons
,Test 6 g Bank 6 g For 6 g Clayton’s 6 g Basic 6 g Pharmacology 3
6 g for 6 g Nurses 6 g 19th
b. Drug 6 g Interaction 6 g Facts
c. Handbook 6 g on 6 g Injectable 6 g Drugs
d. Martindale—The 6 g Complete 6 g Drug 6 g Reference
ANS: 6 g A
Drug 6 g Facts 6 g and 6 g Comparisons 6 g contains 6 g drug 6 g monographs 6 g that
6 g describe 6 g all 6 g drug 6gs 6 g in 6 g a8htherapeutic 6 g class. 6 g Monographs 6 g are
6 g formatted 6 g as 6 g tables 6 g to 6 g allow 6 g compariso 6gn 6gof 6gsimilarproducts, 6gbrand
6gnames, 6gmanufacturers, 6gcost 6gindices, 6gand 6gavailable 6gd 6 g osage 6 g forms 6 g Online
6 g version 6 g is 6 g available.
DIF: Cognitive 6 g Level: 6 g Knowledge REF: p. 6 g 4 6 g Table 6 g 1.2
OBJ: 3 NAT: 6 g 6 g NCLEX 6 g Client 6 g Needs 6 g Category: 6 g Physiological 6 g Integrity
TOP: Nursing 6 g Process 6 g Step: 6 g Assessment 6 g CON: Safety 6 g | 6 g Patient 6 g Education 6 g | 6 g Clinical
6 g Judgment
4. Which 6 g drug 6 g reference 6 g contains 6 g monographs 6 g about 6 g virtually 6 g every 6g single-
entity 6gdrug 6 g availablein 6 g the 6 g United 6 g States 6 g and 6 g describes 6 g therapeutic 6 g uses
6 g of 6 g drugs, 6 g incl 6guding 6 g approved 6 g and 6 g unapproved 6 g uses?
a. Martindale: 6 g The 6 g Complete 6 g Drug 6 g Reference
b. AHFS 6 g Drug 6 g Information
c. Drug 6 g Reference
d. Drug 6 g Facts 6 g and 6 g Comparisons
ANS: 6 g B
AHFS 6 g Drug 6 g Information 6 g contains 6 g monographs 6 g about 6 g virtually 6 g every 6 g single-
entity 6 g drug 6 g available 6 g in 6 g the 6 g United 6 g States 6 g and 6 g describes 6 g therapeutic
6 g uses 6 g of 6 g drugs, 6 g inclu 6gding 6 g approved 6 g and8hunapproved 6 g uses.
DIF: Cognitive 6 g Level: 6 g Knowledge REF: p. 6 g 4 6 g Table 6 g 1.2
OBJ: 3 NAT: 6 g 6 g NCLEX 6 g Client 6 g Needs 6 g Category: 6 g Physiological 6 g Integrity
TOP: Nursing 6 g Process 6 g Step: 6 g Planning CON: Safety 6 g | 6 g Patient 6 g Education 6 g | 6 g Clinical
6 g Judgment
5. Which 6 g online 6 g drug 6 g reference 6 g makes 6 g available 6 g to 6 g healthcare 6 g providers
and 6 g the 6 g publi 6gc 6 g a 6 g standard, 6 g comprehensive, 6 g up-to-
6 g
date 6 g look 6 g up 6 g and 6 g downloadable 6 g resource 6 g about 6 g medicines?
a. American 6 g Drug 6 g Index
b. American 6 g Hospital 6 g Formulary
c. DailyMed
d. Drug 6 g Reference
ANS: 6 g C
DailyMed 6gmakes 6gavailable 6gto 6ghealthcare 6gproviders 6gand 6gthe 6gpublic 6ga 6gstandard,
6gcomprehe 6gnsive,8hup-to-
date 6 g look 6 g up 6 g and 6 g downloadable 6 g resource 6 g about 6 g medicines. 6 g The 6 g American
6 g Drug 6 g Index 6 g i 6gsnot 6 g appropriate 6 g for 6 g patient 6 g use. 6 g The 6 g American 6 g Hospital
6 g Formulary 6 g is 6 g not 6 g appropriate 6gfor 6 g patient 6 g use. 6 g The 6 g drug 6 g reference
6 g is 6 g not 6 g appropriate 6 g for 6 g patient 6 g use.
DIF: Cognitive 6 g Level: 6 g Knowledge REF: p. 6 g 3 6 g | 6 g p. 6 g 4
OBJ: 6 g 3NAT: 6 g NCLEX 6 g Client 6 g Needs 6 g Category:
6 g Physiological 6gIntegrity
TOP: 6 g Nursing 6 g Process 6 g Step: 6 g Implementation
CON: 6 g 6 g Safety 6 g | 6 g Patient 6 g Education 6 g | 6 g Clinical 6 g Judgment
6. Which 6 g legislation 6 g authorizes 6 g the 6 g FDA 6 g to 6 g determine 6 g the 6g safety 6gof 6 g a 6 g drug
6gbefore 6 g its 6 g marketing?
a. Federal 6 g Food, 6 g Drug, 6 g and 6 g Cosmetic 6 g Act 6 g (1938)
b. Durham 6 g Humphrey 6 g Amendment 6 g (1952)
, Test 6 g Bank 6 g For 6 g Clayton’s 6 g Basic 6 g Pharmacology 4
6 g for 6 g Nurses 6 g 19th
c. Controlled 6 g Substances 6 g Act 6 g (1970)
d. Kefauver 6 g Harris 6 g Drug 6 g Amendment 6 g (1962)
ANS: 6 g A
The 6 g Federal 6 g Food, 6 g Drug, 6 g and 6 g Cosmetic 6 g Act 6 g of 6 g 1938 6 g authorized 6 g the
6 g FDA 6 g to 6 g determine 6 g the 6 g safety 6 g of 6 g all 6 g drugs 6 g before 6 g marketing. 6 g Later
6 g amendments 6 g and 6 g acts 6 g helped 6 g tighten 6 g FDA 6 g control 6 g and 6 g ensure 6 g drug
6 g safety. 6 g The 6 g Durham 6 g Humphrey 6 g Amendment 6 g defines 6 g the 6gkinds 6 g of 6 g drugs
6 g that 6 g cannot 6 g be 6 g used 6 g safely 6 g without 6 g medical 6 g supervision 6 g and 6 g restricts
6 g th 6 g eir 6 g sale 6 g to 6 g prescription 6 g by 6 g a 6 g licensed 6 g practitioner. 6 g The 6 g Controlled
6 g Substances 6 g Act 6 g addre 6gsses 6 g only 6 g controlled 6 g substances 6 g andtheir
6 g categorization. 6 g The 6 g Kefauver 6 g Harris 6 g Drug 6 g Ame 6gndment 6 g ensures 6 g drug
6 g efficacy 6 g and 6 g greaterdrug 6 g safety. 6 g Drug 6 g manufacturers 6 g are 6 g required 6gto
6 g prove 6 g to 6 g the 6 g FDA 6 g the 6 g effectiveness 6 g of 6 g their 6 g products 6 g before
6 g marketing 6 g them.
DIF: Cognitive 6 g Level: 6 g Knowledge REF: 6 g p. 6 g 5
6gTable 6 g l.3 6gOBJ: 5
NAT: 6 g NCLEX 6 g Client 6 g Needs 6 g Category: 6 g Physiological
6 g Inte 6ggrity8hTOP: 6 g Nursing 6 g Process 6 g Step: 6 g Assessment
CON: Safety 6 g | 6 g Patient 6 g Education 6 g | 6 g Evidence 6 g | 6 g Health 6 g Care 6 g Law
7. Which 6 g classification 6g does 6 g meperidine 6g (Demerol) 6 g fall 6 g under?
a. I
b. II
c. III
d. IV
ANS: 6 g B
Meperidine 6 g (Demerol) 6 g is 6 g a 6 g Schedule 6 g II 6 g drug; 6 g it 6 g has 6 g a 6 g high
6 g potential 6 g for 6 g abuse 6 g and 6 g m 6gay 6 g lead 6 g tosevere 6 g psychological 6 g and
6 g physical 6 g dependence. 6 g Schedule 6 g I 6 g drugs 6 g have 6 g high 6 g p 6gotential 6 g for
6 g abuseand 6 g no 6 g recognized 6 g medical 6 g use. 6 g Schedule 6 g III 6 g drugs 6 g have 6 g some
6 g potent 6gial 6 g for 6 g abuse. 6 g Use 6 g may 6 g lead 6 g to 6 g low 6 g to 6 g moderate 6 g physical
6 g dependence 6 g or 6 g high 6 g psychol 6 g ogical 6 g dependence. 6 g Schedule 6 g IVdrugs 6 g have
6 g low 6 g potential 6 g for 6 g abuse. 6 g Use 6 g may 6 g lead 6 g to 6 g limited 6 g physical 6 g or
6 g psychological 6 g dependence.
DIF: Cognitive 6 g Level: 6 g Knowledge REF: p. 6 g 10
OBJ: 6 g 2NAT: 6 g NCLEX 6 g Client 6 g Needs 6 g Category:
6 g Safe, 6 g Effectiv 6 g e 6 g Care 6 g Environment
TOP: Nursing 6 g Process 6 g Step: 6 g Assessment 6 g CON: Patient 6 g Education 6 g | 6 g Addiction 6g | 6 g Pain
8. Which action 6 g would 6 g the 6 g FDA 6 g take 6 g to 6 g expedite 6 g drug 6 g development
6g 6 g and
6 g approval 6 g for 6 g an 6 g o 6gutbreakof 6 g smallpox?
a. List 6 g smallpox 6 g as 6 g a 6 g health 6 g orphan 6 g disease.
b. Omit 6 g the 6 g preclinical 6 g research 6 g phase.
c. Extend 6 g the 6 g clinical 6 g research 6 g phase.
d. Fast 6 g track 6 g the 6 g investigational 6 g drug.
ANS: 6 g D
Once 6 g the 6 g Investigational 6 g New 6 g Drug 6 g Application 6 g has 6 g been 6 g approved, 6 g the
6 g drug 6 g can 6 g recei 6 g ve 6 g highest 6 g priority 6 g within 6 g the 6 g agency, 6 g which 6 g is
6 g called 6 g fast 6 g tracking. 6 g A 6 g smallpox 6 g outbr 6 g eak 6 g would 6 g become 6 g a
6 g priority 6 g concern 6 g in 6 g the 6 g world. 6 g Orphan 6 g diseases 6 g are 6 g not 6 g researche
d 6 g in 6 g a 6 g priority 6 g manner. 6 g Preclinical 6 g research 6 g is 6 g not 6 g omitted. 6 g Extending
6 g any 6 g phase 6 g of 6 g th
e 6 g research 6 g would 6 g mean8ha 6 g longer 6 g time 6 g to 6 g develop 6 g a 6 g vaccine. 6 g The 6 g FDA
6 g must 6 g ensure 6 g that 6gall 6gphases 6gof 6gthe 6gpreclinical 6gandclinical 6gresearch 6gphase 6ghave
NURSES 19TH EDITIONBY MICHELLE J. WILLIHNGANZ,
SAMUEL L. GUREVITZ, BRUCE CLAYTON COMPLETE
,Chapter 01: Drug Definitions, Standards, and Information Sources Willihn
ganz: Clayton’s Basic Pharmacology for Nurses, 19th Edition
MULTIPLE CHOIC
E
1. Which name identifies a drug listed by the US Foo
d andDrug Administration (FDA)?
a. Brand
b. Nonproprietary
c. Official
d. Trademark
ANS: C
The official name is the name under which a drug is
listed by the FDA. The brand name, or trademark, is t
he name given to a drug by its manufacturer. The non
DIF: Cognitive
proprietary, 6 g Level: 6 g Knowledge
or generic, name is providedREF: 6 g p. 6 g 9
by6 gthe United
OBJ: 6 g 1NAT: 6 g NCLEX 6 g Client 6 g Needs 6 g Category:
States Adopted Names Council.
6g Safe, 6 g Effective 6gCareEnvironment 6g TOP: Nursing
6g Process 6 g Step: 6 g Assessment
CON:
Patient 6 g Education
2. Which 6 g source 6 g contains 6 g information 6 g specific 6 g to 6 g nutritional 6 g supplements?
a. USP 6 g Dictionary 6 g of 6 g USAN 6 g & 6gInternational 6 g Drug 6 g Names
b. Natural 6 g Medicines 6 g Comprehensive 6 g Database
c. United 6 g States 6 g Pharmacopoeia/National 6 g Formulary 6 g (USP 6 g NF)
d. Drug 6 g Interaction 6 g Facts
ANS: 6 g C
United 6gStates 6gPharmacopoeia/National 6gFormulary 6gcontains 6ginformation 6gspecific 6gto
6gnutriti 6gonalsupplements. 6 g USP 6 g Dictionary 6 g of 6 g USAN 6 g & 6 g International 6 g Drug
6 g Names 6 g is 6 g a 6 g compilat 6gion 6 g of 6 g drug8hnames, 6 g pronunciation 6 g guide, 6 g and
6 g possible 6 g future 6 g FDA 6 g approved 6 g drugs; 6 g it 6 g d 6goes 6gnot 6ginclude 6gnutritional
6gsupplements. 6gNatural 6gMedicines 6gComprehensive 6gDatabase 6gc 6gontains
evidence-
based 6 g information 6 g on 6 g herbal 6 g medicines 6 g and 6 g herbal 6 g combination 6 g products;
6 g it 6 g does 6 g notincl 6gude 6 g information 6 g specific 6 g to 6 g nutritional 6 g supplements. 6 g Drug
6 g Interaction 6 g Facts 6 g contains 6 g co 6gmprehensive 6 g information 6 g on 6 g drug
6 g interaction 6 g facts; 6 g it 6 g does 6 g not 6 g include 6 g nutritional 6 g supp 6 g lements.
DIF: Cognitive 6 g Level: 6 g Knowledge REF: p. 6 g 4
OBJ: 6 g 3NAT: 6 g NCLEX 6 g Client 6 g Needs 6 g Category:
6 g Physiological 6gIntegrity
TOP: Nursing 6 g Process 6 g Step: 6 g Assessment 6 g CON: Nutrition 6g | 6 g Patient 6 g Education
3. Which 6 g drug reference 6 g contains 6 g drug 6 g monographs
6g 6 g that 6 g describe 6 g all 6g drugs 6 g in 6 g a
6 g therapeutic 6 g class?
a. Drug 6 g Facts 6 g and 6 g Comparisons
,Test 6 g Bank 6 g For 6 g Clayton’s 6 g Basic 6 g Pharmacology 3
6 g for 6 g Nurses 6 g 19th
b. Drug 6 g Interaction 6 g Facts
c. Handbook 6 g on 6 g Injectable 6 g Drugs
d. Martindale—The 6 g Complete 6 g Drug 6 g Reference
ANS: 6 g A
Drug 6 g Facts 6 g and 6 g Comparisons 6 g contains 6 g drug 6 g monographs 6 g that
6 g describe 6 g all 6 g drug 6gs 6 g in 6 g a8htherapeutic 6 g class. 6 g Monographs 6 g are
6 g formatted 6 g as 6 g tables 6 g to 6 g allow 6 g compariso 6gn 6gof 6gsimilarproducts, 6gbrand
6gnames, 6gmanufacturers, 6gcost 6gindices, 6gand 6gavailable 6gd 6 g osage 6 g forms 6 g Online
6 g version 6 g is 6 g available.
DIF: Cognitive 6 g Level: 6 g Knowledge REF: p. 6 g 4 6 g Table 6 g 1.2
OBJ: 3 NAT: 6 g 6 g NCLEX 6 g Client 6 g Needs 6 g Category: 6 g Physiological 6 g Integrity
TOP: Nursing 6 g Process 6 g Step: 6 g Assessment 6 g CON: Safety 6 g | 6 g Patient 6 g Education 6 g | 6 g Clinical
6 g Judgment
4. Which 6 g drug 6 g reference 6 g contains 6 g monographs 6 g about 6 g virtually 6 g every 6g single-
entity 6gdrug 6 g availablein 6 g the 6 g United 6 g States 6 g and 6 g describes 6 g therapeutic 6 g uses
6 g of 6 g drugs, 6 g incl 6guding 6 g approved 6 g and 6 g unapproved 6 g uses?
a. Martindale: 6 g The 6 g Complete 6 g Drug 6 g Reference
b. AHFS 6 g Drug 6 g Information
c. Drug 6 g Reference
d. Drug 6 g Facts 6 g and 6 g Comparisons
ANS: 6 g B
AHFS 6 g Drug 6 g Information 6 g contains 6 g monographs 6 g about 6 g virtually 6 g every 6 g single-
entity 6 g drug 6 g available 6 g in 6 g the 6 g United 6 g States 6 g and 6 g describes 6 g therapeutic
6 g uses 6 g of 6 g drugs, 6 g inclu 6gding 6 g approved 6 g and8hunapproved 6 g uses.
DIF: Cognitive 6 g Level: 6 g Knowledge REF: p. 6 g 4 6 g Table 6 g 1.2
OBJ: 3 NAT: 6 g 6 g NCLEX 6 g Client 6 g Needs 6 g Category: 6 g Physiological 6 g Integrity
TOP: Nursing 6 g Process 6 g Step: 6 g Planning CON: Safety 6 g | 6 g Patient 6 g Education 6 g | 6 g Clinical
6 g Judgment
5. Which 6 g online 6 g drug 6 g reference 6 g makes 6 g available 6 g to 6 g healthcare 6 g providers
and 6 g the 6 g publi 6gc 6 g a 6 g standard, 6 g comprehensive, 6 g up-to-
6 g
date 6 g look 6 g up 6 g and 6 g downloadable 6 g resource 6 g about 6 g medicines?
a. American 6 g Drug 6 g Index
b. American 6 g Hospital 6 g Formulary
c. DailyMed
d. Drug 6 g Reference
ANS: 6 g C
DailyMed 6gmakes 6gavailable 6gto 6ghealthcare 6gproviders 6gand 6gthe 6gpublic 6ga 6gstandard,
6gcomprehe 6gnsive,8hup-to-
date 6 g look 6 g up 6 g and 6 g downloadable 6 g resource 6 g about 6 g medicines. 6 g The 6 g American
6 g Drug 6 g Index 6 g i 6gsnot 6 g appropriate 6 g for 6 g patient 6 g use. 6 g The 6 g American 6 g Hospital
6 g Formulary 6 g is 6 g not 6 g appropriate 6gfor 6 g patient 6 g use. 6 g The 6 g drug 6 g reference
6 g is 6 g not 6 g appropriate 6 g for 6 g patient 6 g use.
DIF: Cognitive 6 g Level: 6 g Knowledge REF: p. 6 g 3 6 g | 6 g p. 6 g 4
OBJ: 6 g 3NAT: 6 g NCLEX 6 g Client 6 g Needs 6 g Category:
6 g Physiological 6gIntegrity
TOP: 6 g Nursing 6 g Process 6 g Step: 6 g Implementation
CON: 6 g 6 g Safety 6 g | 6 g Patient 6 g Education 6 g | 6 g Clinical 6 g Judgment
6. Which 6 g legislation 6 g authorizes 6 g the 6 g FDA 6 g to 6 g determine 6 g the 6g safety 6gof 6 g a 6 g drug
6gbefore 6 g its 6 g marketing?
a. Federal 6 g Food, 6 g Drug, 6 g and 6 g Cosmetic 6 g Act 6 g (1938)
b. Durham 6 g Humphrey 6 g Amendment 6 g (1952)
, Test 6 g Bank 6 g For 6 g Clayton’s 6 g Basic 6 g Pharmacology 4
6 g for 6 g Nurses 6 g 19th
c. Controlled 6 g Substances 6 g Act 6 g (1970)
d. Kefauver 6 g Harris 6 g Drug 6 g Amendment 6 g (1962)
ANS: 6 g A
The 6 g Federal 6 g Food, 6 g Drug, 6 g and 6 g Cosmetic 6 g Act 6 g of 6 g 1938 6 g authorized 6 g the
6 g FDA 6 g to 6 g determine 6 g the 6 g safety 6 g of 6 g all 6 g drugs 6 g before 6 g marketing. 6 g Later
6 g amendments 6 g and 6 g acts 6 g helped 6 g tighten 6 g FDA 6 g control 6 g and 6 g ensure 6 g drug
6 g safety. 6 g The 6 g Durham 6 g Humphrey 6 g Amendment 6 g defines 6 g the 6gkinds 6 g of 6 g drugs
6 g that 6 g cannot 6 g be 6 g used 6 g safely 6 g without 6 g medical 6 g supervision 6 g and 6 g restricts
6 g th 6 g eir 6 g sale 6 g to 6 g prescription 6 g by 6 g a 6 g licensed 6 g practitioner. 6 g The 6 g Controlled
6 g Substances 6 g Act 6 g addre 6gsses 6 g only 6 g controlled 6 g substances 6 g andtheir
6 g categorization. 6 g The 6 g Kefauver 6 g Harris 6 g Drug 6 g Ame 6gndment 6 g ensures 6 g drug
6 g efficacy 6 g and 6 g greaterdrug 6 g safety. 6 g Drug 6 g manufacturers 6 g are 6 g required 6gto
6 g prove 6 g to 6 g the 6 g FDA 6 g the 6 g effectiveness 6 g of 6 g their 6 g products 6 g before
6 g marketing 6 g them.
DIF: Cognitive 6 g Level: 6 g Knowledge REF: 6 g p. 6 g 5
6gTable 6 g l.3 6gOBJ: 5
NAT: 6 g NCLEX 6 g Client 6 g Needs 6 g Category: 6 g Physiological
6 g Inte 6ggrity8hTOP: 6 g Nursing 6 g Process 6 g Step: 6 g Assessment
CON: Safety 6 g | 6 g Patient 6 g Education 6 g | 6 g Evidence 6 g | 6 g Health 6 g Care 6 g Law
7. Which 6 g classification 6g does 6 g meperidine 6g (Demerol) 6 g fall 6 g under?
a. I
b. II
c. III
d. IV
ANS: 6 g B
Meperidine 6 g (Demerol) 6 g is 6 g a 6 g Schedule 6 g II 6 g drug; 6 g it 6 g has 6 g a 6 g high
6 g potential 6 g for 6 g abuse 6 g and 6 g m 6gay 6 g lead 6 g tosevere 6 g psychological 6 g and
6 g physical 6 g dependence. 6 g Schedule 6 g I 6 g drugs 6 g have 6 g high 6 g p 6gotential 6 g for
6 g abuseand 6 g no 6 g recognized 6 g medical 6 g use. 6 g Schedule 6 g III 6 g drugs 6 g have 6 g some
6 g potent 6gial 6 g for 6 g abuse. 6 g Use 6 g may 6 g lead 6 g to 6 g low 6 g to 6 g moderate 6 g physical
6 g dependence 6 g or 6 g high 6 g psychol 6 g ogical 6 g dependence. 6 g Schedule 6 g IVdrugs 6 g have
6 g low 6 g potential 6 g for 6 g abuse. 6 g Use 6 g may 6 g lead 6 g to 6 g limited 6 g physical 6 g or
6 g psychological 6 g dependence.
DIF: Cognitive 6 g Level: 6 g Knowledge REF: p. 6 g 10
OBJ: 6 g 2NAT: 6 g NCLEX 6 g Client 6 g Needs 6 g Category:
6 g Safe, 6 g Effectiv 6 g e 6 g Care 6 g Environment
TOP: Nursing 6 g Process 6 g Step: 6 g Assessment 6 g CON: Patient 6 g Education 6 g | 6 g Addiction 6g | 6 g Pain
8. Which action 6 g would 6 g the 6 g FDA 6 g take 6 g to 6 g expedite 6 g drug 6 g development
6g 6 g and
6 g approval 6 g for 6 g an 6 g o 6gutbreakof 6 g smallpox?
a. List 6 g smallpox 6 g as 6 g a 6 g health 6 g orphan 6 g disease.
b. Omit 6 g the 6 g preclinical 6 g research 6 g phase.
c. Extend 6 g the 6 g clinical 6 g research 6 g phase.
d. Fast 6 g track 6 g the 6 g investigational 6 g drug.
ANS: 6 g D
Once 6 g the 6 g Investigational 6 g New 6 g Drug 6 g Application 6 g has 6 g been 6 g approved, 6 g the
6 g drug 6 g can 6 g recei 6 g ve 6 g highest 6 g priority 6 g within 6 g the 6 g agency, 6 g which 6 g is
6 g called 6 g fast 6 g tracking. 6 g A 6 g smallpox 6 g outbr 6 g eak 6 g would 6 g become 6 g a
6 g priority 6 g concern 6 g in 6 g the 6 g world. 6 g Orphan 6 g diseases 6 g are 6 g not 6 g researche
d 6 g in 6 g a 6 g priority 6 g manner. 6 g Preclinical 6 g research 6 g is 6 g not 6 g omitted. 6 g Extending
6 g any 6 g phase 6 g of 6 g th
e 6 g research 6 g would 6 g mean8ha 6 g longer 6 g time 6 g to 6 g develop 6 g a 6 g vaccine. 6 g The 6 g FDA
6 g must 6 g ensure 6 g that 6gall 6gphases 6gof 6gthe 6gpreclinical 6gandclinical 6gresearch 6gphase 6ghave
